Showing results (331-340 of 344) with videos related to
Sort By:
Pageof 35
Japanese Journal of Clinical Oncology|September 2, 2025
Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphomaKen Ohmachi, Tomohiro Kinoshita, Dai Maruyama, et al.The Lancet. Haematology|March 28, 2020
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trialMaria-Victoria Mateos, Hareth Nahi, Wojciech Legiec, et al.Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.DEN Open|May 7, 2025
Clinical backgrounds and outcomes of patients with Barrett's esophageal adenocarcinoma treated via endoscopic submucosal dissection in Kyushu, Japan: A retrospective multicenter cohort studyFumisato Sasaki, Kazuhiro Mizukami, Taro Akashi, et al.Blood Advances|February 16, 2021
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trialKen Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, et al.Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.Cancer Science|July 4, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility studyTakahiko Yasuda, Masashi Sanada, Dai Nishijima, et al.Pageof 35